Salarius Pharmaceuticals, Inc.

Clinical-stage biopharma developing targeted protein therapies for cancer and viral diseases.

SLRX | NDAQ

Overview

Corporate Details

ISIN(s):: US79400X4043 (+1 more)
LEI:
Country:: United States of America
Address:: 2450 HOLCOMBE BLVD, 77021 HOUSTON
Website:: https://salariuspharma.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cancer and other diseases with high unmet medical needs. The company's technology aims to correct the dysregulated gene expression that drives disease progression. Its pipeline is built on two primary drug classes: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials for solid and hematologic cancers like leukemias and lymphomas. The company's TPD candidate, SP-3164, is in IND-enabling studies. Following a merger with Decoy Therapeutics, Salarius is also advancing peptide therapeutics for cancer and respiratory viruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Salarius Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Salarius Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Salarius Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
OKYO Pharma Ltd Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.	United States of America	OKYO
OLIPASS CORPORATION Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.	South Korea	244460
OmniAb, Inc. A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.	United States of America	OABIW
Oncocross Co.,Ltd. AI-powered biotech accelerating drug development for cancer and rare diseases.	South Korea	382150
Onconic Therapeutics Inc. Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.	South Korea	476060
OncoTherapy Science, Inc. Develops targeted cancer therapies and provides TCR repertoire analysis services.	Japan	4564
Onxeo Developing precision-guided therapeutics using small antibodies for complex diseases.	France	ALONX
Openedges Technology, Inc. Semiconductor IP provider of memory subsystem & AI platform IP for AI, HPC, and IoT SoCs.	South Korea	394280
Openjobmetis Employment agency providing staffing, recruitment, and HR services to companies and job seekers.	Italy	OJM
Open Up Group Inc. Provides staffing and outsourcing of engineers for global manufacturing, IT, and construction sectors.	Japan	2154